Progress in ovarian cancer research: Proceedings of the 5th biennial ovarian cancer research symposium

被引:2
作者
Disis, ML
Rivkin, SE
Baron, A
Markman, M
Connolly, D
Ueland, F
Kohn, E
Trimble, E
Berek, JS
机构
[1] Univ Washington, Tumor Vaccine Grp, Seattle, WA 98109 USA
[2] Swedish Med Ctr, Seattle, WA USA
[3] Marsha Rivkin Ctr, Seattle, WA USA
[4] Univ Kentucky, Lexington, KY 40506 USA
[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[7] NCI, Bethesda, MD 20892 USA
[8] Stanford Univ, Sch Med, Stanford Canc Ctr, Stanford, CA 94305 USA
关键词
cancer; ovarian; research; translational;
D O I
10.1111/j.1525-1438.2006.00559.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer remains the most lethal gynecological malignancy. The 5th Biennial Symposium overviewed the progress of ovarian cancer research over the last few years. Molecularly based technologies have allowed the identification of multiple biomarkers to aid in ovarian cancer diagnosis and treatment. Furthermore, data analysis systems evaluating the behavior of these markers have been designed. Therapeutic use of ovarian cancer protein markers has been fueled by the development of animal models that more closely simulate the pathogenesis of ovarian cancer, and multiple new therapies are being developed that may have impact against the disease. Finally, the design of clinical trials both for ovarian cancer treatment and prevention are key in advancing the science of ovarian cancer into the clinic. The need for strategies that would optimize patient participation in clinical trials is paramount.
引用
收藏
页码:463 / 469
页数:7
相关论文
共 20 条
[1]   Worry about ovarian cancer risk and use of screening by high-risk women: How you recruit affects what you find [J].
Andersen, MR ;
Nelson, J ;
Peacock, S ;
Giedzinska, A ;
Dresher, C ;
Bowen, D ;
Urban, N .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2004, 129A (02) :130-135
[2]  
ANDERSEN MR, UNPUB QUALITY LIFE E
[3]   Soluble epidermal growth factor receptor (SEG-FR) and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer [J].
Baron, AT ;
Boardman, CH ;
Lafky, JM ;
Rademaker, A ;
Liu, DC ;
Fishman, DA ;
Podratz, KC ;
Maihle, NJ .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (02) :306-318
[4]   Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group [J].
Bookman, MA ;
Darcy, KM ;
Clarke-Pearson, D ;
Boothby, RA ;
Horowitz, IR .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :283-290
[5]   Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis [J].
Cheng, P ;
Schmutte, C ;
Cofer, KF ;
Felix, JC ;
Yu, MC ;
Dubeau, L .
BRITISH JOURNAL OF CANCER, 1997, 75 (03) :396-402
[6]   Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients [J].
Disis, ML ;
Goodell, V ;
Schiffman, K ;
Knutson, KL .
JOURNAL OF CLINICAL IMMUNOLOGY, 2004, 24 (05) :571-578
[7]  
Drescher CW, 2004, CANCER EPIDEM BIOMAR, V13, P600
[8]   Differential gene expression in ovarian carcinoma - Identification of potential biomarkers [J].
Hibbs, K ;
Skubitz, KM ;
Pambuccian, SE ;
Casey, RC ;
Burleson, KM ;
Oegema, TR ;
Thiele, JJ ;
Grindle, SM ;
Bliss, RL ;
Skubitz, APN .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (02) :397-414
[9]   The fundamental role of epigenetic events in cancer [J].
Jones, PA ;
Baylin, SB .
NATURE REVIEWS GENETICS, 2002, 3 (06) :415-428
[10]   Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells [J].
Katano, K ;
Safaei, R ;
Samimi, G ;
Holzer, A ;
Tomioka, M ;
Goodman, M ;
Howell, SB .
CLINICAL CANCER RESEARCH, 2004, 10 (13) :4578-4588